Targeted development of biosimilar pharmaceutical products
Targeted development of biosimilar pharmaceutical products
Targeted development of biosimilar pharmaceutical products
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Bioassays addressing multiple MoAs<br />
CDC<br />
complement<br />
dependent<br />
cytotoxicity<br />
C1<br />
Membrane<br />
attack<br />
complex<br />
Target cell<br />
FcγRIIIa<br />
Blocking/ Inhibiting RB<br />
Dimerization / Shedding / Internalization<br />
PCD<br />
Effector cell<br />
(NK cells)<br />
ADCC<br />
24 | Thomas Stangler | EAPB SIG Regulatory Aspects for Bio<strong>pharmaceutical</strong>s | October 4th, 2010 | Business use only<br />
Antibody dependent<br />
cellular cytotoxicity<br />
Programmed cell death (apoptosis )